This single-center, retrospective, 7-year observational study aims to investigate prognostic factors in esophageal cancer patients. Adults (≥18 years) with histologically confirmed esophageal cancer who received antitumor therapy between January 2017 and December 2024 were consecutively enrolled. Patient-level data (clinical characteristics, routine laboratory tests, tumor information, and treatment details) were retrospectively collected from electronic medical records to analyze key factors influencing treatment efficacy.
Study Type
OBSERVATIONAL
Enrollment
500
Definitive radiotherapy or radiotherapy-based combined modality therapy
Immune checkpoint inhibitors as monotherapy or in combination with other therapies
Radical esophagectomy with or without neoadjuvant/adjuvant therapy
Nanfang Hospital, Southern Medical University
Guangzhou, Guangzhou, China
Overall Survival (OS)
The length of time from the start of treatment until death from any cause, evaluating the long-term survival benefit of the combined therapy.
Time frame: From the date of treatment initiation to the date of death from any cause,assessed up to 120 months.
Pathologic Complete Response ( pCR )
The absence of residual viable tumor cells in both the primary esophageal tumor and regional lymph nodes after completion of surgery, indicating a complete pathological response.
Time frame: Perioperative
Major Pathological Response Rate (MPR)
The proportion of patients with ≤10% residual viable tumor cells in resected specimens
Time frame: Perioperative
Progression-Free Survival (PFS)
The duration from treatment start until radiologically confirmed disease progression (per RECIST v1.1) or death from any cause, evaluating therapeutic efficacy in delaying tumor growth.
Time frame: From treatment initiation to disease progression or death, assessed up to 100 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.